Foghorn Therapeutics Inc. (FHTX)
NASDAQ: FHTX · Real-Time Price · USD
5.17
-0.04 (-0.77%)
At close: Apr 28, 2026, 4:00 PM EDT
5.17
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Foghorn Therapeutics Employees
Foghorn Therapeutics had 106 employees as of December 31, 2025. The number of employees decreased by 6 or -5.36% compared to the previous year.
Employees
106
Change (1Y)
-6
Growth (1Y)
-5.36%
Revenue / Employee
$291,594
Profits / Employee
-$700,783
Market Cap
303.48M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Abeona Therapeutics | 226 |
| Cabaletta Bio | 156 |
| LENZ Therapeutics | 152 |
| Nautilus Biotechnology | 130 |
| Zentalis Pharmaceuticals | 106 |
| Compass Therapeutics | 39 |
| Inhibikase Therapeutics | 35 |
FHTX News
- 7 days ago - Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting - GlobeNewsWire
- 19 days ago - Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting - GlobeNewsWire
- 6 weeks ago - Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook - GlobeNewsWire
- 2 months ago - Foghorn Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer - GlobeNewsWire
- 2 months ago - Foghorn Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - Transcripts
- 3 months ago - Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit - GlobeNewsWire